TY - JOUR T1 - Peroxiredoxins and their expression in ependymomas JF - Journal of Clinical Pathology JO - J Clin Pathol SP - 12 LP - 17 DO - 10.1136/jclinpath-2012-201048 VL - 66 IS - 1 AU - Toomas Haapasalo AU - Kristiina Nordfors AU - Sally Järvelä AU - Eloise Kok AU - Pauli Sallinen AU - Vuokko L Kinnula AU - Hannu Kalervo Haapasalo AU - Ylermi Soini Y1 - 2013/01/01 UR - http://jcp.bmj.com/content/66/1/12.abstract N2 - Aims Peroxiredoxins I–VI (Prxs) have recently been shown to have a role in the tumorigenesis of astrocytic brain tumours. In some tumour types they are associated with Nrf2 (transcription factor NF-E2-related factor), a sensor of oxidative stress, and DJ-1 (also known as PARK7), a protein known to stabilise Nrf2. Methods We investigated the immunohistochemical expression of Prxs I–VI, Nrf2 and DJ-1 in a total of 76 ependymomas and their relationship with clinicopathological features of these tumours. Results There was a significant expression of all Prxs except Prx IV in the ependymomas. Strong nuclear and cytoplasmic expression of Nrf2 could be detected in these tumours. Prx I expression was significantly associated with cytoplasmic and nuclear Nrf2 expression. Prx I expression was also associated with tumour site, with cerebellar ependymomas having a lower expression of Prx I than other tumours. DJ-1 did not associate with Prxs but nuclear DJ-1 had an inverse association with nuclear Nrf2. Cytoplasmic DJ-1 associated with worse survival in ependymoma patients. Conclusions This study indicates that oxidative mechanisms as reflected by Nrf2 expression are highly activated in ependymomas. Prxs, especially Prx I, were associated with Nrf2 expression, suggesting a role for Nrf2 in Prx I synthesis in ependymomas. While DJ-1 did not associate with any of the Prxs, its expression was associated with worsened patient survival and could have a role as a prognostic marker in ependymomas. ER -